Roel Bogie

Chapter 3

70.9%

• • º P All indications FAP, IBD, SPS, Oka 2009 • • • •/ º R Therapy (?) NA 171/2 NA NA CRC, previous resection 1 1/2 Mean 62 47%

Chiu 2009 • • • • • • • • P Screening NA 2 Mean 51.2 55.8% Urban 2008 • • • • º R Therapy (EMR) NA 4 NA NA syndrome 1 Mean 62.5 58.3%

Males (%)

Duration of study (years) Age of the study population (years)

(SD 9.9)

Prevalence of LSTs Prevalence of patients with LSTs in neoplasm(s) Prevalence of LSTs of all neoplasms Location Endoscopic subtype Histology Kaku 2011 • • • • • • P Screening FIT+ patients 53/4 Mean 58.1 43.1% Kaji 2011 • • • • • P Therapy (EMR, ESD) FAP, IBD, Lynch syndrome 41/2 Mean 68.9 65.3% syndrome 1 Mean 65.8 59.3% Matsuda 2010 • • • • R Therapy (all) NA 5 1/4 Mean 63.4 Bustamante Balén 2010 history of LST term used Serrated lesions excluded Study design

Huang 2009 • • • • • R Therapy (all) FAP, IBD 7 Mean 59 61.5%

Exclusion criteria

Inclusion criteria

Sugimoto 2010 • • º P Therapy (ESD) FAP, IBD, Lynch

Tantau 2008 • • • • • • • • P All indications FAP, IBD, Lynch

LST

definition

Prevalence estimates LST features

Table 3.1: (continuation)

Study

46